Citations

Showing 10 of 108104 citations.

A novel missense mutation in BEST1 associated with an autosomal-dominant vitreoretinochoroidopathy (ADVIRC) phenotype
Mano, Fukutaro , Olsen, Timothy W. , Marmorstein, Alan D. , Pulido, José S. , LoBue, Stephen A , Marmorstein, Alan D

Mayo Clinic

Ophthalmic Genetics | September 17, 2018 | Volume: 39 | Issue: 6 | Pages: 749-753

10.1080/13816810.2018.1520264 | PMID 30222024 Get It

Implementing bedside rounds to improve patient-centred outcomes: a systematic review
Ratelle, John T. , Sawatsky, Adam P. , Kashiwagi, Deanne T. , Schouten, Will M. , Erwin, Patricia J., Gonzalo, Jed D. , Beckman, Thomas J. , West, Colin P.

Mayo Clinic

BMJ Quality & Safety | September 17, 2018 | Volume: 28 | Issue: 4 | Pages: 317-326

10.1136/bmjqs-2017-007778 | PMID 30224407 Get It

Background Bedside rounds (BR) have been proposed as an ideal method to promote patient-centred hospital care, but there is substantial variation in their implementation and effects. Our objectives were to describe the implementation of BR in hospital settings and determine their effect on patient-centred outcomes. Methods Data sources included Ovid MEDLINE, Ovid Embase, Scopus and Ovid Cochrane Central Registry of Clinical Trials from database inception through 28 July 2017. We included experimental studies comparing BR to another form of rounds in a hospital-based setting (ie, medical/surgical unit, intensive care unit (ICU)) and reporting a quantitative patient-reported or objectively measured clinical outcome. We used random effects models to calculate pooled Cohen's d effect size estimates for the patient knowledge and patient experience outcome domains. Results Twenty-nine studies met inclusion criteria, including 20 from adult care (17 non-ICU, 3 ICU), and nine from paediatrics (5 non-ICU, 4 ICU), the majority of which (n=23) were conducted in the USA. Thirteen studies implemented BR with cointerventions as part of a ‘bundle’. Studies most commonly reported outcomes in the domains of patient experience (n=24) and patient knowledge (n=10). We found a small, statistically significant improvement in patient experience with BR (summary Cohen’s d=0.09, 95% CI 0.04 to 0.14, p<0.001, I2=56%), but no significant association between BR and patient knowledge (Cohen’s d=0.21, 95% CI −0.004 to –0.43, p=0.054, I2=92%). Risk of bias was moderate to high, with methodological limitations most often relating to selective reporting, low adherence rates and missing data. Conclusions BR have been implemented in a variety of hospital settings, often ‘bundled’ with cointerventions. However, BR have demonstrated limited effect on patient-centred outcomes.
Black Thyroid
Yu, Nathan Y. , Gamez, Mauricio E. , Yu, Nathan

Mayo Clinic

International Journal of Surgical Pathology | September 17, 2018 | Volume: 27 | Issue: 4 | Pages: 401-402

10.1177/1066896918800773 | PMID 30322317 Get It

Preoperative antibiotics and cardiovascular implantable electronic device infection: A cohort study in veterans
Alzahrani, Talal , Liappis, Angelike P., Karasik, Pamela , Baddour, Larry M.

Mayo Clinic

Pacing and Clinical Electrophysiology | September 17, 2018 | Volume: 41 | Issue: 11 | Pages: 1513-1518

10.1111/pace.13499 | PMID 30221380 Get It

AbstractBackgroundCefazolin is used as standard preoperative prophylaxis for a variety of surgical procedures that involve the skin. In contrast, vancomycin is recommended for a minority of patients, specifically those with an IgE‐mediated allergy to beta‐lactams and considered in patients with known colonization with methicillin‐resistant Staphylococcus aureus or at high risk for such. Vancomycin, however, has been overprescribed, has nephrotoxicity risk, and may be less effective due to its inferior coverage of methicillin‐susceptible S. aureus and lack of Gram‐negative coverage. This study was performed to assess whether vancomycin use was associated with an increased incidence of cardiovascular implantable electronic device infection (CIEDI) as compared to that of cefazolin or other antistaphylococcal beta‐lactam antibiotics.MethodsThe VA Informatics and Computing Infrastructure database, which included all veterans who underwent CIED placement or revision between 2008 and 2015, was used. A logistic regression model was constructed to estimate the adjusted odds of CIEDI.ResultsOverall, 10,454 CIED procedures were included, and 98% of them were performed in men with a mean age of 71 ± 12 years. The logistic regression analysis showed that vancomycin use alone or in combination with other antibiotics was associated with an increased risk of CIEDI (odds ratio 2.99 [1.76–5.06], P‐value < 0.001), after controlling for other effects.ConclusionsOur study revealed that among patients who received surgical site infection prophylaxis for CIED placement or revision, there was: (1) an unanticipated high rate of vancomycin use, and (2) a threefold increase in the incidence of subsequent CIEDI among vancomycin recipient
Personalized ESA doses for anemia management in hemodialysis patients with end‐stage renal disease
Rogers, James R. , Gallaher, Edward J., Dingli, David

Mayo Clinic

System Dynamics Review | September 17, 2018 | Volume: 34 | Issue: 1-2 | Pages: 121-153

10.1002/sdr.1606 Get It

AbstractEnd‐stage renal disease (ESRD) patients receiving hemodialysis are typically anemic due to a lack of erythropoietin (EPO), a hormone required for red blood cell (RBC) production. EPO replacement therapy is complex, often resulting in oscillating hemoglobin (Hb) levels. EPO dosing protocols do not account for endogenous delays and appear to contribute to, if not cause, Hb variability. The Mayo Clinic Anemia Management System (MCAMS) is based on a physiological simulation of the production and lifespan of RBCs, driven by EPO dosage schedules. Patient‐specific parameters were found such that simulated Hb levels matched historical Hb levels in response to historical EPO doses. The calibrated model was used to identify new dosing regimens that stabilize Hb. MCAMS has been used to recommend individualized EPO dosage regimens to maintain stable Hb levels within a desired target range for more than 600 patients, improving patient outcomes while reducing medication costs by about 40 percent.© 2018 System Dynamics Society
Low to Intermediate Dose Atropine Administration During Dobutamine Stress Echocardiography in the Pre-Liver Transplant Population
Snipelisky, David , Shipman, Justin , Olson, Nicole, Pellikka, Patricia A. , Aqel, Bashar , McCully, Robert B. , Watt, Kymberly D. , Pellikka, Patricia, McCully, Robert, Watt, Kymberly, Pellikka, Patricia A , Aqel, Bashar A.

Mayo Clinic

Progress in Transplantation | September 17, 2018 | Volume: 28 | Issue: 4 | Pages: 361-367

10.1177/1526924818800048 | PMID 30222085 Get It

Introduction: Dobutamine stress echocardiography (DSE) is frequently used to screen for obstructive coronary artery disease in the pre-liver transplant evaluation. Although atropine is a commonly used adjunctive medication, no study has evaluated its side effect profile in patients with end-stage liver disease (ESLD). Research Question: What is the safety of atropine in candidates undergoing pre-liver transplant evaluation when atropine is used in stress testing? Design: This multicenter, prospective study enrolled patients over a 6-month period undergoing pre-liver transplant evaluation. Each patient completed a questionnaire assessing anticholinergic-related symptoms within 24 hours of testing and 48 hours following. Comparisons were made among patients receiving any atropine dose versus those who did not and among patients receiving at least 1 mg atropine and those receiving less/none. Results: Forty patients were evaluated, and 32 (80%) had adjunctive atropine administered. No differences in clinical characteristics were noted. In comparisons among patients receiving any dose of atropine with those who did not, questionnaire results indicated a higher rate of nausea prior to testing and higher overall symptom severity following testing in patients not receiving atropine. In comparisons among patients receiving less than 1 mg atropine with those receiving at least 1 mg atropine, no difference in pre- or posttesting questionnaire responses was present. No patient in the study required reversal agents or hospitalization within 7 days of testing. Conclusions: Atropine, a hepatically metabolized medication, did not predispose patients with ESLD to an increased symptom burden, and clinical outcomes related to DSE were unaffected.
Outcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death
Madhavan, Malini , Waks, Jonathan W. , Friedman, Paul A. , Kramer, Daniel B. , Buxton, Alfred E. , Mehta, Ramila A. , Hodge, David O. , Higgins, Angela , Webster, Tracy L., Witt, Chance M. , Cha, Yong‐Mei , Higgins, Angela Y. , Noseworthy, Peter A. , Gersh, Bernard J.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | September 17, 2018 | Volume: 9 | Issue: 3 | Pages: No page available

10.1161/circep.115.003283 | PMID 26921377 Get It

Background— The effectiveness of implantable cardioverter-defibrillators (ICDs) for primary prevention of sudden death in patients with an ejection fraction (EF) ≤35% and clinical heart failure is well established. However, outcomes after replacement of the ICD generator in patients with recovery of EF to >35% and no previous therapies are not well characterized. Methods and Results— Between 2001 and 2011, generator replacement was performed at 2 tertiary medical centers in 253 patients (mean age, 68.3±12.7 years; 82% men) who had previously undergone ICD placement for primary prevention but subsequently never received appropriate ICD therapy. EF had recovered to >35% in 72 of 253 (28%) patients at generator replacement. During median (quartiles) follow-up of 3.3 (1.8–5.3) years after generator replacement, 68 of 253 (27%) experienced appropriate ICD therapy. Patients with EF ≤35% were more likely to experience ICD therapy compared with those with EF >35% (12% versus 5% per year; hazard ratio, 3.57; P =0.001). On multivariable analysis, low EF predicted appropriate ICD therapy after generator replacement (hazard ratio, 1.96 [1.35–2.87] per 10% decrement; P =0.001). Death occurred in 25% of patients 5 years after generator replacement. Mortality was similar in patients with EF ≤35% and >35% (7% versus 5% per year; hazard ratio, 1.10; P =0.68). Atrial fibrillation (3.24 [1.63–6.43]; P <0.001) and higher blood urea nitrogen (1.28 [1.14–1.45] per increase of 10 mg/dL; P <0.001) were associated with mortality. Conclusions— Although approximately one fourth of patients with a primary prevention ICD and no previous therapy have EF >35% at the time of generator replacement, these patients continue to be at significant risk for appropriate ICD therapy (5% per year). These data may inform decisions on ICD replacement.
Successful Antimicrobial Treatment of Phlegmonous Gastritis: A Case Report and Literature Review
Iqbal, Madiha , Saleem, Rabia , Jani, Prachi, Álvarez, Salvador, Ahmed, Salman , Tun, Han W. , Iqbal, Madiha , Ahmed, Salman

Mayo Clinic

Case Reports in Hematology | September 16, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-5

10.1155/2018/8274732 | PMID 30305967 Get It

Phlegmonous gastritis is an uncommon acute bacterial infection of the stomach that carries a fatal prognosis in spite of the advent of antibiotics. A high index of suspicion is required in patients with risk factors. An immunocompromised state is identified as one of the most important risk factors. We hereby report a case of successful antimicrobial treatment of phlegmonous gastritis in a patient who was receiving intensive chemotherapy for acute myelogenous leukemia. We have also carried out a review of literature over the past ten years. Streptococcus pyogenes is identified as the most common causative organism, and patient presentation is usually nonspecific. Conservative treatment with prompt institution of antibiotics can lead to rapid resolution in the majority of patients.
Systemic Lupus Erythematosus Presenting with Alveolar Hemorrhage
Tolaymat, Omar , Berianu, Florentina

Mayo Clinic

Case Reports in Rheumatology | September 16, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-3

10.1155/2018/8218904 | PMID 30305976 Get It

Introduction. Diffuse alveolar hemorrhage is a rare presentation of systemic lupus erythematosus. Early diagnosis and appropriate treatment can improve outcome. Case Report. An 18-year-old male presented with hemoptysis and respiratory distress requiring orotracheal intubation. Laboratory tests showed positive anti-nuclear antibody and anti-dsDNA and low C3 and C4. Bronchoalveolar lavage became progressively hemorrhagic after each aliquot. He was treated with pulse methylprednisolone, cyclophosphamide, and plasma exchanges. Discussion. Alveolar hemorrhage is a rare initial presentation of lupus, with mortality rates reported at about 50%. Lupus should be considered in those presenting with alveolar hemorrhage since delay in therapy may cause a rapid deterioration of the patient. The diagnosis of SLE is illusive when DAH is the presenting symptom. Since early diagnosis and appropriate institution of treatment improve outcome, it is important to keep lupus in mind as an etiology of alveolar hemorrhage. Pulse methylprednisolone, cyclophosphamide, and plasmapheresis therapy resulted in rapid improvement of respiratory function in our patient.
Risk of Infective Endocarditis Due to Invasive Dental Procedures
Prendergast, Bernard , Baddour, Larry M.

Mayo Clinic

Circulation | September 16, 2018 | Volume: 138 | Issue: 4 | Pages: 364-366

10.1161/circulationaha.118.035393 | PMID 30571373 Get It